Inclusion Criteria:

- Hospital in- or out-patients

- Either sex

- Aged 18-75 years

- With hepatocellular carcinoma, verified by histology/cytology, which is not amenable
to curative treatment or transplantation.

- Patients must have measurable disease, and be classifiable as to Barcelona Clinic
Liver Cancer (BCLC) stage 0, as described in Llovet JM et al. Hepatology
1999;29:62-67.

Exclusion Criteria:

- Patients treated with chemotherapy or other anti-cancer therapy within 4 weeks before
visit 1

- Patients with another primary tumor, except for basocellular carcinoma of the skin or
in situ carcinoma of the cervix, within the last 2 years

- A history of renal stone(s)

- A life expectancy of < 3 months

- World Health Organization (WHO) performance status 3 or 4

- Okuda stage III.

- Patients with hypercalcemia, or other clinically important laboratory abnormalities

- Patients with previous/current calcium metabolic disease, taking calcium-lowering
therapy, or medication known to affect systemic calcium metabolism are also excluded.

- All patients must give their signed informed consent to join the study.